ASX Company Announcements

The edited text of our announcements are sourced from the Australian Stock Exchange and are delayed by at least 20 minutes. Retrieving the edited text of a company announcement indicates your acceptance of the Conditions.

Cellmid does not take any responsibility in respect of any of the edited text sourced from the Australian Stock Exchange


 Appendix 4G and Corporate Governance Statement


 2019 Annual Report to shareholders


 FY19 Results Presentation 


 Appendix 4E and FY19 Financial Report


 FY2019 Financial Results


 Patent for Improved Midkine Antibody Allowed in Europe


 Cellmid signs distribution agreement for Evolis in South Korea


 Appendix 4C Query


 Appendix 3B New issue annoucement, application for quotation of additional securities and   agreement


 Cellmid Notes to the Appendix 4C


 Cellmid Investor Newsletter


 ASX Aware Query


 Cellmid sets another sales record in Q4 FY2019


 Change of Director's Interest Notice 


 Cellmid appoints Lyramid CEO to Accelerate Partnering


 FY2020 Growth Strategy Update May 2019


 Minimum holding buy-back completed


 Minimum holding buy-back closed


 Appendix 3Y - Change of Director's Interest Notice


 Cellmid's evolis registered in European Union


 Cellmid notes to the Appendix 4C


 Repayment of Cellmid loan issued to Director pursuant to employee incentive plan


 Cellmid Alopecia Patent allowed in Europe


 Cellmid Investor Newsletter March 2019


 Minimum Holding Share Buy-Back


 Appendix 4D, Half Year Accounts and Strategy Update


 Significant New Findings Published On MIDKINE


 Appendix 4C and Notes to Appendix 4C